Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

BiondVax Universal Influenza Vaccine Candidate Trial Does Not Meet Primary, Secondary Endpoints

americanpharmaceuticalreviewOctober 29, 2020

Tag: BiondVax , M-001 , flu vaccine , Clinical Trial

PharmaSources Customer Service